Literature DB >> 8486759

Importance of factor Xa in determining the procoagulant activity of whole-blood clots.

P R Eisenberg1, J E Siegel, D R Abendschein, J P Miletich.   

Abstract

The binding of thrombin to fibrin is thought to be an important mechanism by which thrombi exhibit procoagulant activity; however, the extent to which other procoagulants are associated with thrombi has not been previously defined. This study was designed to determine whether clotting factors other than thrombin are bound to whole-blood clots and can thereby contribute to significant procoagulant activity. Clots formed in vitro from human blood exhibited minimal thrombin activity when incubated in plasma depleted of vitamin K-dependent factors by barium-citrate adsorption, as indicated by increases in the concentration of fibrinopeptide A (FPA), a marker of fibrin formation, to 72 nM after 30 min. Incubation of clots in barium-absorbed plasma repleted with 0.9 microM human prothrombin under the same conditions resulted in marked increases in the concentration of FPA (> 1,000 nM) and clotting by 30 min. The increases in FPA were attributable to activation of the added prothrombin by clot-associated Factor Xa, judging from concomitant increases in the concentration of prothrombin fragment 1.2. Similar results were obtained with thrombi induced in the axillary arteries of dogs by vascular injury and incubated with plasma in vitro. Activation of prothrombin was inhibited in a dose-dependent manner by tick anticoagulant peptide, a direct inhibitor of Factor Xa, at concentrations of 0.5-5.0 microM. Clot-associated Factor Xa activity was resistant to inhibition by anti-thrombin III, judging from the lack of inhibition of prothrombin activation during incubation of clots in plasma containing heparin pentasaccharide, an anti-thrombin III-mediated inhibitor of Factor Xa. Thus, the activity of Factor Xa appears to be an important determinant of the procoagulant activity of whole-blood clots and arterial thrombi, and is resistant to inhibition by anti-thrombin III-dependent inhibitors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486759      PMCID: PMC288180          DOI: 10.1172/JCI116404

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

Review 1.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

Authors:  K G Mann; M E Nesheim; W R Church; P Haley; S Krishnaswamy
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

2.  Selective immobilization of alpha-thrombin by surface-bound fibrin.

Authors:  G D Wilner; M P Danitz; M S Mudd; K H Hsieh; J W Fenton
Journal:  J Lab Clin Med       Date:  1981-03

3.  Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite.

Authors:  C Kockum; S Frebelius
Journal:  Thromb Res       Date:  1980 Aug 15-Sep 1       Impact factor: 3.944

4.  Structural studies on a biologically active hexasaccharide obtained from heparin.

Authors:  J Choay; J C Lormeau; M Petitou; P Sinaÿ; J Fareed
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

Authors:  C Kettner; E Shaw
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

6.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

Authors:  J I Weitz; M Hudoba; D Massel; J Maraganore; J Hirsh
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

7.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

9.  Thrombin activity of fibrin thrombi and soluble plasmic derivatives.

Authors:  C W Francis; R E Markham; G H Barlow; T M Florack; D M Dobrzynski; V J Marder
Journal:  J Lab Clin Med       Date:  1983-08

10.  Measurement of fibrinopeptide A in human blood.

Authors:  H L Nossel; I Yudelman; R E Canfield; V P Butler; K Spanondis; G D Wilner; G D Qureshi
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  11 in total

Review 1.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors:  Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal:  Nat Rev Drug Discov       Date:  2010-12-17       Impact factor: 84.694

Review 2.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  Rivaroxaban delivery and reversal at a venous flow rate.

Authors:  Laura M Haynes; Thomas Orfeo; Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-27       Impact factor: 8.311

4.  Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.

Authors:  S S Rebello; R G Bentley; S R Morgan; C J Kasiewski; V Chu; M H Perrone; R J Leadley
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

5.  Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 6.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 7.  Oral anticoagulants in older adults with atrial fibrillation.

Authors:  Gwen M Bernacki; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

8.  Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement.

Authors:  Lars C Borris; Morten Breindahl; Michael R Lassen; Akos F Pap
Journal:  Thrombosis       Date:  2011-05-03

9.  Laboratory assessment of rivaroxaban: a review.

Authors:  Meyer Michel Samama; Geneviève Contant; Theodore E Spiro; Elisabeth Perzborn; Lena Le Flem; Céline Guinet; Yves Gourmelin; Gabriele Rohde; Jean-Luc Martinoli
Journal:  Thromb J       Date:  2013-07-03

Review 10.  The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm.

Authors:  Keren Borensztajn; Jan H von der Thüsen; Maikel P Peppelenbosch; C Arnold Spek
Journal:  J Cell Mol Med       Date:  2009-11-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.